Search

Intellia Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

12.83 3.05

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.81

Max

12.98

Galvenie mērījumi

By Trading Economics

Ienākumi

-107M

-203M

Pārdošana

-7.4M

7.7M

EPS

-0.8

Peļņas marža

-2,648.714

Darbinieki

377

EBITDA

-11M

-105M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+62.77% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

189M

1.7B

Iepriekšējā atvēršanas cena

9.78

Iepriekšējā slēgšanas cena

12.83

Ziņu noskaņojums

By Acuity

60%

40%

287 / 340 Rangs Healthcare

Intellia Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

2026. g. 20. aug. 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

2026. g. 19. aug. 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

2026. g. 17. aug. 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

2026. g. 14. aug. 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

2026. g. 11. aug. 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

2026. g. 10. aug. 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

2026. g. 7. aug. 19:26 UTC

News
Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

2026. g. 6. aug. 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

2026. g. 4. aug. 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

2026. g. 3. aug. 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

2026. g. 31. jūl. 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

2026. g. 30. jūl. 17:57 UTC

Correlated Moves
News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

2026. g. 29. jūl. 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

2026. g. 28. jūl. 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

2026. g. 27. jūl. 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

2026. g. 25. jūl. 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

2026. g. 24. jūl. 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

2026. g. 23. jūl. 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

2026. g. 22. jūl. 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

2026. g. 21. jūl. 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

2026. g. 20. jūl. 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Salīdzinājums

Cenas izmaiņa

Intellia Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

62.77% augšup

Prognoze 12 mēnešiem

Vidējais 20.9 USD  62.77%

Augstākais 49 USD

Zemākais 9 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Intellia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

6

Pirkt

4

Turēt

2

Pārdot

Noskaņojums

By Acuity

287 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat